Effect of ayurveda drug Jatamansi in patients suffering from depressio
- Conditions
- Health Condition 1: F321- Major depressive disorder, singleepisode, moderate
- Registration Number
- CTRI/2021/01/030417
- Lead Sponsor
- Central Council for Research in Ayurveda Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients of Vishada according to Ayurveda parameters and Major Depressive Disorder as per ICD-10: moderate depression (HDRS scores of 17-23), prescribed with Escitalopram 10-20mg for < 2 months.
Subjects of either gender in the age group of 18 to 45 years
Patients willing to participate in the study and give informed written consent
Patients suffering from any other known cardiorespiratory, neurological or endocrinological, systemic disorders as assessed by history and detailed clinical examination
Patients suffering from other psychiatric disorders: alcohol/substance abuse, psychotic features (Anya manovaha sroto vikara), suicidal tendency (Na prana Akanksha)
Female patients who are pregnant or lactating (Garbhini and Soothika)
Depression with suicidal tendency/ thoughts Other psychotic disorders Cardiovascular disorders
Patients with contraindications for TMS (Transcranial magnetic stimulation): Major head injury, epilepsy, metallic implants anywhere in the body
Patients who have completed participation in any other clinical trial during the past six (06) months and any other condition which the Investigators think may jeopardize the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hamilton depression rating scaleTimepoint: Baseline, 28th day, 56th day, 84th day
- Secondary Outcome Measures
Name Time Method Heart rate variability <br/ ><br>Transcranial magnetic stimulation <br/ ><br>Plasm Brain derived neurotrophic factor <br/ ><br>Serum glutamate receptor antibodiesTimepoint: Baseline, 56th day